Saltar al contenido
Merck

SML1569

Sigma-Aldrich

Acotiamide dihydrochloride

≥98% (HPLC)

Sinónimos:

N-[2-[bis(1-Methylethyl)amino]ethyl]-2-[(2-hydroxy-4,5-dimethoxybenzoyl)amino]-4-Thiazolecarboxamide dihydrochloride, N-[2-[bis(1-Methylethyl)amino]ethyl]-2-[(2-hydroxy-4,5-dimethoxybenzoyl)amino]thiazole-4-carboxamide dihydrochloride, YM-443 dihydrochloride, Z-338 dihydrochloride

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C21H30N4O5S · 2HCl
Número de CAS:
Peso molecular:
523.47
Número MDL:
Código UNSPSC:
12352200
NACRES:
NA.77

Nivel de calidad

Análisis

≥98% (HPLC)

formulario

powder

condiciones de almacenamiento

desiccated

color

white to beige

solubilidad

H2O: 20 mg/mL, clear

temp. de almacenamiento

−20°C

cadena SMILES

CC(C)N(C(C)C)CCNC(C1=CSC(NC(C2=CC(OC)=C(OC)C=C2O)=O)=N1)=O.Cl[H]

InChI

1S/C21H30N4O5S/c1-12(2)25(13(3)4)8-7-22-20(28)15-11-31-21(23-15)24-19(27)14-9-17(29-5)18(30-6)10-16(14)26/h9-13,26H,7-8H2,1-6H3,(H,22,28)(H,23,24,27)

Clave InChI

TWHZNAUBXFZMCA-UHFFFAOYSA-N

Acciones bioquímicas o fisiológicas

Acotiamide is a potent, selective and reversible inhibitor of human and canine stomach-derived acetylcholinesterase (AChE). Acotiamide showed no affinity for dopamine D2 or serotonin 5-HT4 receptors but does have activity as a muscarinic antagonist. It acts as a prokinetic drug through acetylcholinesterase inhibition and muscarinic receptor antagonism, and has been used for the treatment of functional dyspepsia (FD) involving gastric motility dysfunction.

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Norihisa Ishimura et al.
BMC gastroenterology, 15, 117-117 (2015-09-13)
The prevalence of gastroesophageal reflux disease (GERD) has been increasing worldwide, with proton pump inhibitor (PPI) administration the current mainstay therapy for affected individuals. However, PPI efficacy is insufficient especially for non-erosive reflux disease. Although it has been reported that
K Ito et al.
Drug research, 66(4), 196-202 (2015-09-30)
Acotiamide is a first-in-class prokinetic drug approved in Japan for the treatment of functional dyspepsia. Given that acotiamide enhances gastric motility in conscious dogs and rats, we assessed the in vitro effects of this drug on the contraction of guinea
Alkesh V Zala et al.
Expert opinion on emerging drugs, 20(2), 221-233 (2015-02-04)
Functional dyspepsia (FD) is a relatively common gastrointestinal clinical condition that remains poorly understood. Controversies remain regarding the definition, pathophysiology and optimum treatment. The current treatment of FD is limited and no established regimen is available. Recent advances have improved

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico